CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+14.98%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$787M
AUM Growth
+$787M
(+53%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
29.03%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
459
New
34
Increased
332
Reduced
39
Closed
19
Top Buys
| 1 |
Microsoft
MSFT
|
$18.2M |
| 2 |
NVIDIA
NVDA
|
$11.9M |
| 3 |
Netflix
NFLX
|
$9.94M |
| 4 |
Amazon
AMZN
|
$7.89M |
| 5 |
Meta Platforms (Facebook)
META
|
$7.84M |
Top Sells
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.64M |
| 2 |
Alibaba
BABA
|
$2.59M |
| 3 |
XYZ
Block, Inc.
XYZ
|
$2.4M |
| 4 |
Intel
INTC
|
$2.07M |
| 5 |
Coca-Cola
KO
|
$1.91M |
Sector Composition
| 1 | Technology | 37.36% |
| 2 | Healthcare | 29.98% |
| 3 | Consumer Discretionary | 13.6% |
| 4 | Communication Services | 8.97% |
| 5 | Financials | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Ventyx Biosciences
VTYX
$171M
| $62.6K | 0.01% |
11,385
+4,553
| +67% | +$25K |
|
402
Humacyte
HUMA
$245M
| $61.8K | 0.01% |
19,883
+7,897
| +66% | +$24.6K |
|
403
Rambus
RMBS
$7.94B
| $61.8K | 0.01% |
1,000
-23,000
| -96% | -$1.42M |
|
404
Atour Lifestyle Holdings
ATAT
$5.38B
| $61.1K | 0.01% |
3,407
-26,260
| -89% | -$471K |
|
405
Erasca
ERAS
$445M
| $59.8K | 0.01% |
29,013
+11,541
| +66% | +$23.8K |
|
406
RAPT Therapeutics
RAPT
$188M
| $59.3K | 0.01% |
6,602
+2,621
| +66% | +$23.5K |
|
407
Xeris Biopharma Holdings
XERS
$1.26B
| $58.6K | 0.01% |
26,516
+10,543
| +66% | +$23.3K |
|
408
AC Immune
ACIU
$205M
| $56.3K | 0.01% |
19,008
+9,334
| +96% | +$27.6K |
|
|
EXAI
409
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $53K | 0.01% |
9,274
+4,029
| +77% | +$23K |
|
410
uniQure
QURE
$896M
| $51.6K | 0.01% |
9,922
+3,664
| +59% | +$19.1K |
|
411
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $51.2K | 0.01% |
21,426
+8,546
| +66% | +$20.4K |
|
412
Ambarella
AMBA
$3.5B
| $50.8K | 0.01% |
1,000
| – | – |
|
413
Phibro Animal Health
PAHC
$1.5B
| $50.3K | 0.01% |
3,888
+1,531
| +65% | +$19.8K |
|
|
BLUE
414
DELISTED
bluebird bio
BLUE
| $46.8K | 0.01% |
36,580
+23,933
| +189% | +$30.6K |
|
415
TAL Education Group
TAL
$6.46B
| $46.5K | 0.01% |
+4,100
| New | +$46.5K |
|
416
Vanda Pharmaceuticals
VNDA
$279M
| $45.4K | 0.01% |
11,045
+4,387
| +66% | +$18K |
|
417
Align Technology
ALGN
$10.3B
| $43.6K | 0.01% |
133
| – | – |
|
418
Ovid Therapeutics
OVID
$91M
| $41.4K | 0.01% |
13,579
+5,401
| +66% | +$16.5K |
|
419
Hyatt Hotels
H
$13.8B
| $38.3K | ﹤0.01% |
240
| – | – |
|
420
Texas Roadhouse
TXRH
$11.5B
| $37.7K | ﹤0.01% |
244
+200
| +455% | +$30.9K |
|
421
Amylyx Pharmaceuticals
AMLX
$836M
| $36.9K | ﹤0.01% |
13,004
+5,189
| +66% | +$14.7K |
|
|
ME
422
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $32.3K | ﹤0.01% |
60,653
+24,604
| +68% | +$13.1K |
|
423
Edwards Lifesciences
EW
$47.8B
| $24.5K | ﹤0.01% |
256
| – | – |
|
424
Charles River Laboratories
CRL
$8.04B
| $24.1K | ﹤0.01% |
89
| – | – |
|
425
Skechers
SKX
$9.48B
| $22.9K | ﹤0.01% |
374
-10,000
| -96% | -$613K |
|